Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
All three belong to a drug class called GLP-1 receptor agonists, originally developed to treat type 2 diabetes and later found to cause significant weight loss as a side effect
In: Program and abstracts of the American Diabetes Association (ADA) 68th Sessions, June 6-10, 2008, San Francisco, California
It is used to map pathway outputs such as cAMP/PKA signaling, ERK phosphorylation, immediate early gene expression, and downstream transcriptional programs
That trial is expected to end in 2027
US$ 26.76
US$ 22.10
US$ 25.25
US$ 24.16
US$ 28.81
US$ 29.40
US$ 21.22
